Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK, interviews Professor Jihui Hao from the Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, on the paper "CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells" published in paper copy in Gut in December 2024. A close transcript of this podcast is available at this link: https://bit.ly/3Ox8Io2 Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://spoti.fi/3Ifxq9p).
Dr Philip Smith, Digital and Education Editor of Gut and Honorary Consultant Gastroenterologist at the Royal Liverpool Hospital, Liverpool, UK, interviews Professor Jihui Hao from the Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, on the paper "CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells" published in paper copy in Gut in December 2024.
A close transcript of this podcast is available at this link: https://bit.ly/3Ox8Io2
Please subscribe to the Gut podcast on your favourite platform to get the latest podcast every month. If you enjoy our podcast, you can leave us a review or a comment on Apple Podcasts (https://apple.co/3UOTwqS) or Spotify (https://spoti.fi/3Ifxq9p).